Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basic pharmacology of esmolol.

R J Gorczynski

    The American Journal of Cardiology
    |October 23, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Esmolol, an ultrashort-acting beta blocker, demonstrates cardioselectivity with minimal side effects. Its properties make it suitable for treating supraventricular tachycardias and acute myocardial ischemia, especially in critically ill patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.

    Journal of the American College of Cardiology·2000
    Same author

    In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agent.

    Thrombosis research·1991
    Same author

    Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749).

    The Journal of pharmacology and experimental therapeutics·1991
    Same author

    Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.

    Circulation·1989
    Same author

    Beta-adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol.

    Journal of cardiovascular pharmacology·1988
    Same author

    Cardiovascular effects of chronic high-dose atriopeptin III infusion in normotensive rats.

    Toxicology and applied pharmacology·1987

    Area of Science:

    • Cardiovascular Pharmacology
    • Clinical Electrophysiology

    Background:

    • Esmolol is an ultrashort-acting, cardioselective beta-blocker.
    • It exhibits minimal partial agonist and membrane-depressant properties.
    • Its cardiovascular actions are primarily attributed to beta-blockade.

    Purpose of the Study:

    • To evaluate the electrophysiologic and hemodynamic effects of esmolol.
    • To determine the potential therapeutic applications of esmolol.
    • To assess the safety and utility of esmolol in critically ill patients.

    Main Methods:

    • Preclinical studies were conducted to investigate esmolol's properties.
    • Laboratory experiments assessed beta receptor-dependent and independent actions.
    • Electrophysiologic and hemodynamic parameters were analyzed.

    Related Experiment Videos

    Main Results:

    • Esmolol effectively slows atrioventricular conduction and increases atrioventricular refractoriness.
    • It decreases determinants of myocardial oxygen demand.
    • No direct cardiovascular actions independent of beta-blockade were identified at therapeutic doses.

    Conclusions:

    • Esmolol's properties suggest utility in treating supraventricular tachycardias and acute myocardial ischemia.
    • Its ultrashort duration of action ensures safety for initiating beta blockade in critically ill patients.
    • Esmolol is well-suited for managing rapidly fluctuating beta blockade requirements in critical care settings.